CAS 338992-53-3

U0126 TFA

Description:

U0126 TFA, with the CAS number 338992-53-3, is a selective inhibitor of the mitogen-activated protein kinase (MAPK) pathway, specifically targeting the extracellular signal-regulated kinases (ERK1 and ERK2). This compound is often utilized in biochemical research to study cellular signaling pathways and their implications in various diseases, including cancer. U0126 TFA is typically characterized by its ability to inhibit the phosphorylation of ERK, thereby blocking downstream signaling events that are crucial for cell proliferation and survival. The compound is usually provided as a trifluoroacetate salt (TFA), which enhances its solubility in organic solvents and biological media. U0126 TFA is often used in cell culture experiments and in vivo studies to elucidate the role of the MAPK pathway in cellular processes. Its effectiveness and specificity make it a valuable tool in pharmacological research, particularly in the development of targeted therapies. However, as with any chemical substance, proper handling and safety precautions should be observed due to its potential biological effects.

Formula: C₂₂H₂₄BrFN₄O₂.C₂HF₃O₂

Synonyms:

• 4-Quinazolinamine, N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methyl-4-piperidinyl)metho xy]-, mono(trifluoroacetate)

Vandetanib trifluoroacetate

CAS: 338992-53-3

Vandetanib trifluoroacetate: oral VEGFR2/KDR inhibitor, IC50=40nM, also blocks VEGFR3/FLT4 (110nM) and EGFR/HER1 (500nM).

Formula: C₂₄H₂₅BrF₄N₄O₄

Color and Shape: Solid

Molecular weight: 589.386

Ref: TM-T64176

Vandetanib trifluoroacetate

CAS: 338992-53-3

Vandetanib trifluoroacetate is a peptide that belongs to the group of activators. It is a high-purity, water soluble, and stable compound. Vandetanib trifluoroacetate can be used in research as an activator of ion channels and receptors. It can also be used as a tool to study protein interactions with ligands and receptors. The pharmacological effects of Vandetanib trifluoroacetate are highly specific for particular receptor subtypes, such as TrkA or TrkB. Vandetanib trifluoroacetate has been shown to inhibit the activation of the protooncogene c-Jun N-terminal kinase (JNK) by inhibiting phosphorylation at Thr183/Tyr185 sites in response to elevated intracellular calcium concentration, leading to apoptosis.

Formula: C₂₄H₂₅BrF₄N₄O₄

Purity: Min. 95%

Molecular weight: 589.4 g/mol

Ref: 3D-NNA99253